GW to raise $179M, KDEV’s portfolio value sinks to new low, BIA wants U.K. to rival CA, MA

Nick Paul Taylor

In this week's EuroBiotech Report, GW Pharmaceuticals is once again turning to U.S. investors to fuel the advance of its cannabis-based pipeline. The latest offering could generate upward of $ 180 million (€161 million), a sum that will give GW the firepower to mount a multi-front R&D program. And more.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS